ZEALAND PHARMA/S (NASDAQ:ZEAL) and iCo Therapeutics (OTCMKTS:ICOTF) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.
Risk & Volatility
ZEALAND PHARMA/S has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, iCo Therapeutics has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500.
Valuation & Earnings
This table compares ZEALAND PHARMA/S and iCo Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ZEALAND PHARMA/S||$6.02 million||106.51||$92.07 million||$3.00||6.94|
|iCo Therapeutics||N/A||N/A||-$1.30 million||N/A||N/A|
ZEALAND PHARMA/S has higher revenue and earnings than iCo Therapeutics.
Insider & Institutional Ownership
9.1% of ZEALAND PHARMA/S shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares ZEALAND PHARMA/S and iCo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations and price targets for ZEALAND PHARMA/S and iCo Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ZEALAND PHARMA/S currently has a consensus target price of $31.00, indicating a potential upside of 48.85%. Given ZEALAND PHARMA/S’s higher possible upside, research analysts clearly believe ZEALAND PHARMA/S is more favorable than iCo Therapeutics.
ZEALAND PHARMA/S beats iCo Therapeutics on 7 of the 8 factors compared between the two stocks.
ZEALAND PHARMA/S Company Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company’s product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH; and Alexion Pharmaceuticals, Inc. for the discovery and development of peptide therapies for complement-mediated diseases. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
iCo Therapeutics Company Profile
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.
Receive News & Ratings for ZEALAND PHARMA/S Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com’s FREE daily email newsletter.